Multiple Myeloma: Issue 2

The content will be in the form of review articles, but the volume format will allow for much more in-depth discussion than the typical journal review article. The goal will be to provide for the practicing clinician a source of thorough, ongoing analysis and translational assessment of hot topicsA" and areas of rapidly emerging new data in cancer therapeutics with significant implications for clinical care. The second issue of Emerging Cancer Therapeutics focuses on multiple myelomas also known as plasma cell myeloma, Kahler's Disease and myelomatosis. It is estimated that over 20,000 new cases are diagnosed each year with over 10,000 people dying from these malignancies. Multiple myelomas are highly treatable but rarely curable. Thus it is crucial for the practitioner to be up-to-date on the latest insights regarding their management. Management options and outcomes for individuals with multiple myelomas improved dramatically with the introduction of chemotherapy. Even further improvements in prognosis have occurred because of the introduction of newer therapies such as pulse corticosteroids, thalidomide, bortezomib, and autologous and allogeneic stem cell transplantation. With the increased number of therapeutic options to choose from, the clinician is better placed to offer effective therapy nut at the same time is challenged to keep abreast of the rapidly changing treatment landscape and the newly emerging data that is shaping the treatment options today and in the future. Multiple Myeloma provides a comprehensive and in-depth review of this group of malignancies. This volume reviews the current literature, provides critical evaluations of the data and offers evidence-based recommendations. Written by leaders in their fields, chapters update the epidemiology of multiple myeloma, genetic abnormalities in myeloma, MGUS, Initial therapy, the role of stem transplantation, risk factors and management.